



## Committee/Group 'Triple A' Chair's Report

Name of Committee/Group	QUALITY COMMITTEE	Reporting to:	TRUST BOARD
Date of the meeting:	14 March 2019	Parent Committee:	TRUST BOARD
Chair:	Mark Baker, Non-Executive Director	Quorate (Y/N)	Y

Agenda Item:	RAG	Key Points	Actions Required	Action Lead	Expected Date for Completion
Quality Committee Risk Register	Yellow	Haemato-Oncology – Meditech MAR issue for IP SACT: Meditech functionality does not distinguish between 'stopped' and inactive medications after midnight in SACT. Therefore, the Trust will not progress with EP implementation until the MAR issue has been resolved.	The MAR issue has been logged with Meditech as a critical issue since 2016 as still no resolution. This is a <b>project risk</b> rather than a clinical risk.	Julie Massey	April 2019
	Red	Unavailability of Radioisotope labelled white cell scans for infection imaging: The Royal radiopharmacy previously provided Nuclear Medicine at CCC, with a white cell labelling service for patients with suspected infection of prosthesis (28 referrals in the last year). The service is no longer available and there is no current suitable alternative Imaging to this service for patients, as alternative Imaging is less specific.	PETCT can be performed in some cases for infection but there is little evidence base for PETCT in prosthetic infection. There is a possibility of performing Bone SPECT CT with limited expertise. There is currently no suitable alternative available	Julie Massey	June 2019
Safeguarding	Green	The Deprivation of Liberty Safeguards (DoLS) application process which required further development to ensure a robust and sustainable pathway is in place is now complete and a process is in place.	No further action required.	Sarah Barr	Complete

Agenda Item:	RAG	Key Points	Actions Required	Action Lead	Expected Date for Completion
		Mandatory Training: Compliance with Safeguarding Level 3 training for Children, Adults, and Prevent remains below the required contractual and Trust compliance threshold.	A Safeguarding training delivery plan is in place to address this by June 2019.	Jackie Rooney	June 2019
		There is a lack of assurance regarding DBS compliance in that it may result in non-adherence to the Lampard Guidance.	An action plan in place and is being led by Workforce and Organisational Development	Jayne Shaw	End of April 2019
Radiotherapy		The radiotherapy activity variation from plan has improved but remains below plan and further analysis of data on activity remains difficult to access. Current activity for Radiotherapy (at Month 9) increased during the latter part of 2018 and the position at month 9 was that activity was 3.5% below plan.	Further work to be undertaken to determine whether underperformance is due to an increase in active surveillance rates or an increase in referrals to robotic surgery. If this is the case, assurance will be sought that this is a valid treatment option that is being chosen by the patient.	Julie Massey	June 2019
Preparing for Digital Transition		GDE Key Delivery Milestone – this work is moving at pace, with the majority of commitments complete or on track. NHS Digital attended at the Trust on 13 March, and the Trust was able to provide assurance on a number of areas.	A peer review has been undertaken by Alder Hey, and it is anticipated that there will be no issues in relation to obtaining the further future funding.	Sarah Barr	End of April 2019
		The pilot of 'Digital Speech' has been a success with clinicians, and an improvement has been seen in the uploading of notes, and the quality of those notes.	Work will be undertaken to assist all remaining clinicians with the transition of the new system.	Sarah Barr	End of April 2019
		Peer review/Assurance: NHS Digital has improved the Trust's rating, as a result of the evidence provided, from its current rating of Amber Green to Green.	Preparations are underway for the next assurance milestone in April 2019.	Sarah Barr	April 2019

#### KEY

	<b>ALERT</b> the Committee on areas of non-compliance or matters that need addressing urgently
	<b>ADVISE</b> the Committee on any on-going monitoring where an update has been provided to the sub-committee and any new developments that will need to be communicated or included in operational delivery
	<b>ASSURE</b> the Committee on any areas of assurance that the Committee/Group has received